KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Investment Securities: 2009-2025

Historic Gains from Investment Securities for Neogenomics (NEO) over the last 15 years, with Jun 2025 value amounting to $458,000.

  • Neogenomics' Gains from Investment Securities rose 426.44% to $458,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $576,000, marking a year-over-year increase of 53.19%. This contributed to the annual value of $207,000 for FY2024, which is 18.29% up from last year.
  • Neogenomics' Gains from Investment Securities amounted to $458,000 in Q2 2025, which was up 508.93% from -$112,000 recorded in Q4 2024.
  • In the past 5 years, Neogenomics' Gains from Investment Securities ranged from a high of $458,000 in Q2 2025 and a low of -$112,000 during Q4 2024.
  • Over the past 3 years, Neogenomics' median Gains from Investment Securities value was $116,000 (recorded in 2024), while the average stood at $140,000.
  • As far as peak fluctuations go, Neogenomics' Gains from Investment Securities crashed by 2,550.00% in 2021, and later spiked by 2,700.00% in 2022.
  • Quarterly analysis of 5 years shows Neogenomics' Gains from Investment Securities stood at $35,000 in 2021, then dropped by 28.57% to $25,000 in 2022, then soared by 35.66% to $175,000 in 2023, then plummeted by 50.29% to -$112,000 in 2024, then surged by 426.44% to $458,000 in 2025.
  • Its last three reported values are $458,000 in Q2 2025, -$112,000 for Q4 2024, and $143,000 during Q3 2024.